 Preliminary studies immunotherapeutic approach treatment human myeloma chimeric antibody Multiple myeloma disease conventional chemotherapy limited value ideal treatment passive antibody suitable cell surface antigen neoplastic plasma cell antigen present majority neoplastic plasma cells detailed examination bone marrow aspirates patients Strong expression cells criteria light-scattering profiles possession cytoplasmic Ig plasma cells vast majority neoplastic plasma cells cell line model antigen target chimeric antibody antibody chimeric antibody Fab portion mouse monoclonal antibody stable thioether bond Fc molecule human Fab-human Fc contrast parent antibody chimeric molecule antibody-dependent cellular cytotoxicity ADCC human blood mononuclear effector cells effective low concentration antigen present natural killer cells little deleterious action antibody effector cell function antibody growth progenitor cells granulocyte/macrophage erythroid lineages normal bone marrows suspicion cells antigen Other advantages molecule serum patients myeloma vitro Fourteen patients florid myeloma various chemotherapeutic regimes undiminished capacity ADCC chimeric antibody normal individuals maintenance ADCC activity known suppression antibody response patients augers treatment chimeric antibody